With a Large Patient Population, High Medical Need, and a Difficult Development Path, the Sepsis Drug Market is Commercially Attractive but Risky
Posted on: Tuesday, 9 May 2006, 09:03 CDT
WALTHAM, Mass., May 9 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the severity of sepsis, along with the dearth of upcoming competition and lack of safe and effective therapies targeting the systemic inflammatory response, makes this indication commercially attractive. According to the report entitled Sepsis -- Search for a Safe Drug Targeting the Inflammatory/Coagulation Cascade, given the drawbacks of Lilly's Xigris (significant side effects, contraindications), novel agents that can target the inflammatory/coagulation cascade and offer a safer profile are needed.
The report also finds that there is significant risk associated with entering the market.
"The complex nature of sepsis pathophysiology and the heterogeneous population make clinical development in sepsis a risky undertaking for biopharmaceutical manufacturers," says John Lebbos, M.D., analyst at Decision Resources. "Indeed, several highly promising approaches (anti-tumor necrosis factor, antithrombin III, antiplatelet activating factor, tissue factor pathway inhibitor) have failed in clinical trials."
About Sepsis -- Search for a Safe Drug Targeting the Inflammatory/Coagulation Cascade
Sepsis -- Search for a Safe Drug Targeting the Inflammatory/Coagulation Cascade covers the current state of the sepsis drug market. The report includes the following:
* Analysis of the sepsis market focused on the diagnosed/drug-treated populations, patient/market share projections, cost per day, and compliance expectations. * High prescribing physicians identify the specific clinical trial end points that most impact prescribing and project the patient share such an advance would capture. * A ten-year forecast that builds on drug development advances and physician acceptance balanced by payer constraints and generic introductions.
The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
- Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
- Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
- China's Renal Cell Carcinoma Drug Market Will Grow More Than Five-Fold By 2012
- Novel Glycopeptides and Cephalosporins Will Drive the Hospital-Acquired Infections Drug Market Through 2017
- China's Gastric Cancer Drug Market to Triple By 2012, Says Report
- New Drugs From Novartis and Daiichi Sankyo Will Achieve Blockbuster Status in the Hypertension Drug Market
- Next Generation of HIV Antiretrovirals Will Help Drive the HIV Drug Market to More Than $10 Billion in 2015
- Crohn's Disease Drug Market to Experience Dynamic Growth of 73% By 2013
 |
 |
User Comments (0)
RSS Feeds